IFN-α: A key therapeutic target for multiple autoimmune rheumatic diseases.

Frédéric De Ceuninck, Fanny Duguet, Audrey Aussy, Laurence Laigle, Philippe Moingeon

Drug discovery today 2021 Oct

filter terms:

Interferon (IFN)-α has emerged as a major therapeutic target for several autoimmune rheumatic diseases. In this review, we focus on clinical and preclinical advances in anti-IFN-α treatments in systemic lupus erythematosus (SLE), primary Sjögren syndrome (pSS), systemic sclerosis (SSc), and dermatomyositis (DM), for which a high medical need persists. Promising achievements were obtained following direct IFN-α neutralization, targeting its production through the cytosolic nucleic acid sensor pathways or by blocking its downstream effects through the type I IFN receptor. We further focus on molecular profiling and data integration approaches as crucial steps to select patients most likely to benefit from anti-IFN-α therapies within a precision medicine approach. Copyright © 2021 Elsevier Ltd. All rights reserved.

Citation

Frédéric De Ceuninck, Fanny Duguet, Audrey Aussy, Laurence Laigle, Philippe Moingeon. IFN-α: A key therapeutic target for multiple autoimmune rheumatic diseases. Drug discovery today. 2021 Oct;26(10):2465-2473